The DTAB sub-committee on FDC, which held its third meeting on October 30 to decide the fate of around 30 combinations falling in the category of gastro-intestinal drugs, did not approve a single product as the expert panel asked the industry to come out with more scientific data to prove these products' safety and efficacy.
The details can be read here.
No comments:
Post a Comment